首页> 外文期刊>Basic & clinical pharmacology & toxicology. >The legal failure to prevent subclinical developmental toxicity.
【24h】

The legal failure to prevent subclinical developmental toxicity.

机译:未能预防亚临床发育毒性的法律规定。

获取原文
获取原文并翻译 | 示例
       

摘要

Legal systems appear to function poorly to identify and prevent subclinical developmental toxic effects in children that can lead to long-term harm. In the USA, the vast majority of substances enter commerce without any legally required testing (under so-called 'post-market' laws). In 1984, less than 20% of all substances had been subject to pre-market testing and there has been little change since. Once substances are suspected of contributing to harm, an administration agency has the burden to show risks or harms and their causes, an increasingly difficult demonstration. Post-market laws tend to produce no data prior to exposures and any protections result after some harm may have occurred. Pre-market screening laws such as the US Toxic Substances Control Act provide little data or protection. Pre-market testing and approval laws, analogous to US drug and pesticide laws, offer better approaches for identifying and eliminating toxicants before they result in harm, but do not apply to many products andrarely include concerns for developmental toxicity. The Registration, Evaluation, Authorization and Restriction of Chemicals legislation in the European Union has greater promise for the identification of new or existing toxicants. However, the potential for serious, subtle subclinical developmental effects provides reasons to pursue a more precautionary approach to identifying potential toxicants and forestalling harms. This paper sketches a more robust precautionary law and a more substantial departure from existing laws that would treat chemical invasions as trespasses. The scientific community can assist legal efforts by credibly publicizing the seriousness of subclinical developmental effects.
机译:法律制度在识别和预防儿童的亚临床发展性毒性作用方面表现不佳,可能导致长期伤害。在美国,绝大多数物质未经任何法律要求的检测(根据所谓的“上市后”法律)进入商业。 1984年,只有不到20%的物质受到了上市前测试,此后几乎没有变化。一旦怀疑物质造成危害,管理机构就必须承担显示危险或危害及其原因的负担,这是越来越困难的示范。上市后法律倾向于在暴露之前不产生任何数据,并且可能在发生某些损害之后提供任何保护。诸如《美国有毒物质控制法》之类的上市前筛查法律几乎没有提供任何数据或保护。类似于美国药品和农药法律,售前测试和批准法律提供了更好的方法来鉴定和消除有毒有害物质,以免造成危害,但不适用于许多产品,并且很少涉及对发育毒性的关注。欧盟的化学品注册,评估,授权和限制法规对于鉴定新的或现有的有毒物质具有更大的希望。然而,潜在的,严重的,亚临床的亚临床发展效应为寻求更预防性的方法识别潜在的毒物和预防危害提供了理由。本文勾画出了更强大的预防法,并且与现有法律相比有了更大的变化,而现有法律将化学入侵视为侵入。科学界可以通过可靠地宣传亚临床发展效应的严重性来协助法律工作。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号